Celldex Therapeutics, Inc. — Director's Dealing 2016

Dec 15, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2016-12-14

Reporting Person: LaVallee Theresa (SVP, Reg.& Precision Medicine)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-12-14	Incentive Stock Option (right to buy)	$3.72	A	75000	Acquired	2026-12-14	Common Stock (75000)	Direct

Footnotes

F1: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.

F2: 25% of the total amount of shares subject to the Option vests on December 14, 2017 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters, beginning March 14, 2018.